ArticleCureus2024
Unraveling Histiocytic Disorders: Two Cases From Resource-Limited Settings.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histiocytic disorders include a range of uncommon illnesses marked by the buildup of cells that have developed into macrophages, dendritic cells, or monocytes in diverse tissues and organs. Over 100 distinct subtypes have been documented, exhibiting a diverse array of clinical symptoms, presentations, and histologic features that can be confused with other clinical conditions leading to delayed diagnosis. They affect both children and adults, generating a variety of clinical symptoms that can be limited to one position, numerous areas within one system, or affect many systems in the body. We provide our experiences handling two cases of histiocytic disease in underdeveloped countries where targeted treatment choices are unavailable. The first patient was a 32-year-old female with polyuria, skin lesions, and macroadenoma on MRI. Histopathological and immune-histochemical assessment of skin lesions confirmed the diagnosis of Langerhans cell histiocytosis. The patient responded well to steroids and oral and intrathecal methotrexate. The second patient was a 38-year-old male with recurrent skin lesions followed by retro-orbital discomfort and proptosis. The retro-orbital mass was surgically excised followed by a recurrence a few months later. Histopathological and immune-histochemical assessment confirmed the diagnosis of extranodal Rosai-Dorfman disease. He showed a partial response to methotrexate followed by a remarkable response to rituximab. Because of the wide variety of clinical symptoms, the diversity of experts engaged in assessing and treating these patients, and the scarcity of cases accessible, there is still a need to develop an evidence-based technique for evaluating and treating this complicated disease, especially in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.